AbbVie Stock At $190: Premium Pricing For A Transformation Story
1. AbbVie's stock rose 6% in 2024 amid broader market declines. 2. Post-Humira challenges saw Humira's sales drop 58% in recent years. 3. AbbVie pursued $22 billion in acquisitions to diversify revenue streams. 4. Aggressive acquisitions like ImmunoGen and Cerevel Therapeutics enhance growth prospects. 5. High valuation reflects investor confidence in AbbVie's growth and strategy.